

Jan van Meerbeeck

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1376145/publications.pdf>

Version: 2024-02-01

292
papers

23,297
citations

10351

72
h-index

8835

145
g-index

299
all docs

299
docs citations

299
times ranked

19586
citing authors

#	ARTICLE	IF	CITATIONS
1	The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 39-51.	0.5	3,162
2	Small-cell lung cancer. <i>Lancet</i> , The, 2011, 378, 1741-1755.	6.3	941
3	Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2007, 99, 442-450.	3.0	647
4	Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. <i>Journal of Clinical Oncology</i> , 2005, 23, 6881-6889.	0.8	601
5	Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. <i>Lancet</i> , The, 2010, 375, 1267-1277.	6.3	555
6	Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. <i>European Respiratory Journal</i> , 2010, 35, 479-495.	3.1	548
7	The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1204-1223.	0.5	530
8	Mediastinoscopy vs Endosonography for Mediastinal Nodal Staging of Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2245.	3.8	517
9	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 914-922.	5.1	503
10	Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. <i>New England Journal of Medicine</i> , 2020, 383, 931-943.	13.9	500
11	Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. <i>Journal of Clinical Oncology</i> , 1998, 16, 145-152.	0.8	493
12	Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v103-v115.	0.6	456
13	Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. <i>Lancet Oncology</i> , The, 2017, 18, 1116-1125.	5.1	415
14	The International Association for the Study of Lung Cancer Staging Project: Prognostic Factors and Pathologic TNM Stage in Surgically Managed Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 792-801.	0.5	387
15	Proteomic Analysis of Exosomes Isolated from Human Malignant Pleural Effusions. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2004, 31, 114-121.	1.4	366
16	The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1109-1121.	0.5	342
17	The International Association for the Study of Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 300-311.	0.5	338
18	Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1631-1639.	0.5	334

#	ARTICLE	IF	CITATIONS
19	The Impact of Additional Prognostic Factors on Survival and their Relationship with the Anatomical Extent of Disease Expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the Proposals for the 7th Edition. <i>Journal of Thoracic Oncology</i> , 2008, 3, 457-466.	0.5	315
20	Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. <i>Lancet</i> , The, 2007, 369, 1929-1937.	6.3	296
21	Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.. <i>Journal of Clinical Oncology</i> , 1998, 16, 2133-2141.	0.8	260
22	Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. <i>European Respiratory Journal</i> , 2010, 36, 1362-1369.	3.1	231
23	Treatment of Brain Metastases of Small-Cell Lung Cancer: Comparing Teniposide and Teniposide With Whole-Brain Radiotherapyâ€™ A Phase III Study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 2000, 18, 3400-3408.	0.8	223
24	The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 651-665.	0.5	211
25	The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1433-1446.	0.5	201
26	Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 1541-1549.	0.8	199
27	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, 194-207.	0.5	186
28	The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. <i>Journal of Thoracic Oncology</i> , 2016, 11, 639-650.	0.5	182
29	Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. <i>European Respiratory Journal</i> , 2010, 35, 202-215.	3.1	176
30	The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2112-2119.	0.5	172
31	The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the TNM Classification. <i>Journal of Thoracic Oncology</i> , 2016, 11, 666-680.	0.5	170
32	Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. <i>European Respiratory Journal</i> , 1997, 10, 1547-1551.	3.1	159
33	Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. <i>The Cochrane Library</i> , 2015, 2015, CD011430.	1.5	158
34	Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. <i>Annals of Oncology</i> , 2006, 17, 1698-1704.	0.6	156
35	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. <i>European Respiratory Journal</i> , 2020, 55, 1900953.	3.1	151
36	EBUS-TBNA for the diagnosis of central parenchymal lung lesions not visible at routine bronchoscopy. <i>Lung Cancer</i> , 2009, 63, 45-49.	0.9	150

#	ARTICLE	IF	CITATIONS
37	The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2089-2099.	0.5	139
38	Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. <i>Supportive Care in Cancer</i> , 2011, 19, 1753-1760.	1.0	133
39	EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. <i>Annals of Oncology</i> , 2010, 21, 692-706.	0.6	129
40	Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. <i>Lung Cancer</i> , 2017, 107, 100-107.	0.9	128
41	A phase II study of gemcitabine in patients with malignant pleural mesothelioma. <i>Cancer</i> , 1999, 85, 2577-2582.	2.0	125
42	Advances in the systemic therapy of malignant pleural mesothelioma. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 136-147.	4.3	124
43	Evaluation of the solitary pulmonary nodule: size matters, but do not ignore the power of morphology. <i>Insights Into Imaging</i> , 2018, 9, 73-86.	1.6	124
44	Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. <i>Lung Cancer</i> , 2004, 43, 63-69.	0.9	122
45	The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2100-2111.	0.5	120
46	Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naïve patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 569-580.	5.2	117
47	Malignant pleural mesothelioma: The standard of care and challenges for future management. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 78, 92-111.	2.0	115
48	Predicting Risk of Radiation-Induced Lung Injury. <i>Journal of Thoracic Oncology</i> , 2007, 2, 864-874.	0.5	113
49	Comparison of imaging TNM [(i)TNM] and pathological TNM [pTNM] in staging of bronchogenic carcinoma. <i>European Journal of Cardio-thoracic Surgery</i> , 1997, 12, 224-227.	0.6	111
50	EBUS-TBNA for the Clarification of PET Positive Intra-Thoracic Lymph Nodes: an International Multi-Centre Experience. <i>Journal of Thoracic Oncology</i> , 2009, 4, 44-48.	0.5	108
51	A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP). <i>Journal of Thoracic Oncology</i> , 2011, 6, 1078-1086.	0.7	108
52	Endoscopic Ultrasound Reduces Surgical Mediastinal Staging in Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 531-535.	2.5	106
53	Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer Lung Cancer Group Phase III Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 3947-3955.	0.8	102
54	The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 681-692.	0.5	101

#	ARTICLE	IF	CITATIONS
55	Raman microspectroscopic mapping studies of human bronchial tissue. <i>Journal of Biomedical Optics</i> , 2004, 9, 1187.	1.4	97
56	Patient-reported outcome measures (PROMs) in the management of lung cancer: A systematic review. <i>Lung Cancer</i> , 2017, 113, 140-151.	0.9	96
57	Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study. <i>Annals of Oncology</i> , 2001, 12, 1359-1368.	0.6	95
58	Morbidity and mortality in the surgery arm of EORTC 08941 trial. <i>European Respiratory Journal</i> , 2005, 26, 192-197.	3.1	93
59	Health-Related Quality of Life in Non-Small-Cell Lung Cancer: An Update of a Systematic Review on Methodologic Issues in Randomized Controlled Trials. <i>Journal of Clinical Oncology</i> , 2011, 29, 2104-2120.	0.8	92
60	Esophageal Endoscopic Ultrasound With Fine-Needle Aspiration With an On-site Cytopathologist. <i>Chest</i> , 2005, 128, 3004-3009.	0.4	89
61	Defining a standard set of patient-centred outcomes for lung cancer. <i>European Respiratory Journal</i> , 2016, 48, 852-860.	3.1	88
62	Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. <i>Lancet Oncology</i> , 2019, 20, 1702-1709.	5.1	88
63	Diagnostic Performance of Soluble Mesothelin and Megakaryocyte Potentiating Factor in Mesothelioma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 620-625.	2.5	87
64	The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 344-359.	0.5	87
65	Has 3-D conformal radiotherapy (3D CRT) improved the local tumour control for stage I non-small cell lung cancer?. <i>Radiotherapy and Oncology</i> , 2002, 63, 151-157.	0.3	84
66	ESR/ERS statement paper on lung cancer screening. <i>European Radiology</i> , 2020, 30, 3277-3294.	2.3	83
67	Development and External Validation of Prognostic Model for 2-Year Survival of Non-Small-Cell Lung Cancer Patients Treated With Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 355-362.	0.4	82
68	Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1930-1937.	0.5	79
69	Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 790-798.	0.8	79
70	Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. <i>British Journal of Cancer</i> , 1996, 74, 961-963.	2.9	78
71	Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675). <i>Journal of Thoracic Oncology</i> , 2021, 16, 840-849.	0.5	78
72	Symptoms and Patient-Reported Well-Being: Do They Predict Survival in Malignant Pleural Mesothelioma? A Prognostic Factor Analysis of EORTC-NCIC 08983: Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma. <i>Journal of Clinical Oncology</i> , 2007, 25, 5770-5776.	0.8	76

#	ARTICLE	IF	CITATIONS
73	The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1615-1626.	0.5	74
74	Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol. <i>Cancers</i> , 2019, 11, 458.	1.7	73
75	Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients. <i>Radiotherapy and Oncology</i> , 2010, 97, 455-461.	0.3	70
76	Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. <i>Cancer Treatment Reviews</i> , 2014, 40, 990-1004.	3.4	70
77	Short-Term Treatment-Related Symptoms and Quality of Life: Results From an International Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 1435-1442.	0.8	69
78	Endoscopic and Endobronchial Ultrasonography According to the Proposed Lymph Node Map Definition in the Seventh Edition of the Tumor, Node, Metastasis Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1576-1584.	0.5	69
79	Supplementary Prognostic Variables for Pleural Mesothelioma: A Report from the IASLC Staging Committee. <i>Journal of Thoracic Oncology</i> , 2014, 9, 856-864.	0.5	68
80	Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 300-313.	2.0	68
81	Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma. <i>Oncotarget</i> , 2017, 6, e1261241.	2.1	67
82	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 771-779.	5.2	65
83	A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 329-337.	0.5	62
84	The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 22666-22679.	0.8	62
85	Implicit attitudes towards smoking predict long-term relapse in abstinent smokers. <i>Psychopharmacology</i> , 2015, 232, 2551-2561.	1.5	61
86	The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2082-2088.	0.5	61
87	The scent of COVID-19: viral (semi-)volatiles as fast diagnostic biomarkers?. <i>Journal of Breath Research</i> , 2020, 14, 042001.	1.5	61
88	Short Report from the European Society of Medical Oncology: Oral Abstracts on Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2007, 2, 101.	0.5	60
89	Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program. <i>Journal of Thoracic Oncology</i> , 2008, 3, 764-771.	0.5	59
90	Second line therapy in malignant pleural mesothelioma: A systematic review. <i>Lung Cancer</i> , 2015, 89, 223-231.	0.9	56

#	ARTICLE	IF	CITATIONS
91	Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma: a cross-sectional case-control study. <i>Oncotarget</i> , 2017, 8, 91593-91602.	0.8	55
92	Impact of microRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer. <i>Current Pharmaceutical Biotechnology</i> , 2014, 15, 475-485.	0.9	54
93	Prevalence of atopy, asthma and COPD in an urban and a rural area of an African country. <i>Respiratory Medicine</i> , 2011, 105, 1596-1605.	1.3	53
94	Use of the lung cancer-specific Quality of Life Questionnaire EORTC QLQ-LC13 in clinical trials: A systematic review of the literature 20 years after its development. <i>Cancer</i> , 2015, 121, 4300-4323.	2.0	52
95	Caelyx, a gemtuzumab derivative, in malignant mesothelioma: A phase II EORTC study. <i>Annals of Oncology</i> , 2000, 11, 697-700.	0.6	51
96	TERAVOLT: Thoracic Cancers International COVID-19 Collaboration. <i>Cancer Cell</i> , 2020, 37, 742-745.	7.7	51
97	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 58, 1-24.	0.6	50
98	The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 801-809.	0.5	49
99	Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients. <i>Pharmacogenomics</i> , 2010, 11, 1053-1063.	0.6	47
100	Rehabilitation in patients with radically treated respiratory cancer: A randomised controlled trial comparing two training modalities. <i>Lung Cancer</i> , 2015, 89, 167-174.	0.9	47
101	Volatile organic compounds in human matrices as lung cancer biomarkers: a systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103037.	2.0	47
102	A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENDritic cell Immunotherapy for Mesothelioma (DENIM) trial. <i>Translational Lung Cancer Research</i> , 2019, 8, 280-285.	1.3	46
103	Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). <i>European Journal of Cancer</i> , 2013, 49, 2815-2822.	1.3	45
104	The Effect of Clinical Covariates on the Diagnostic and Prognostic Value of Soluble Mesothelin and Megakaryocyte Potentiating Factor. <i>Chest</i> , 2012, 141, 477-484.	0.4	44
105	Multimodal management of malignant pleural mesothelioma: where are we today?. <i>European Respiratory Journal</i> , 2014, 44, 754-764.	3.1	44
106	ALK and crizotinib: after the honeymoon what else? Resistance mechanisms and new therapies to overcome it. <i>Translational Lung Cancer Research</i> , 2014, 3, 250-61.	1.3	44
107	Recent developments in the treatment of small cell lung cancer. <i>European Respiratory Review</i> , 2021, 30, 210079.	3.0	43
108	Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients. <i>Oncotarget</i> , 2017, 8, 89722-89735.	0.8	43

#	ARTICLE	IF	CITATIONS
109	Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?. <i>Oncotarget</i> , 2017, 8, 53751-53762.	0.8	42
110	Targeting immune checkpoints: New opportunity for mesothelioma treatment?. <i>Cancer Treatment Reviews</i> , 2015, 41, 914-924.	3.4	41
111	The Accuracy of Clinical Staging of Stage I-IIa Non-Small Cell Lung Cancer. <i>Chest</i> , 2019, 155, 502-509.	0.4	41
112	Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1994, 424, 631-634.	1.4	40
113	Epidemiology Of Interstitial Lung Disease (ILD). <i>Acta Clinica Belgica</i> , 1995, 50, 260-268.	0.5	39
114	Health-related quality of life in small-cell lung cancer: a systematic review on reporting of methods and clinical issues in randomised controlled trials. <i>Lancet Oncology</i> , The, 2014, 15, e78-e89.	5.1	39
115	A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. <i>Annals of Oncology</i> , 1994, 5, 653-655.	0.6	38
116	Progression-Free Survival Rate As Primary End Point for Phase II Cancer Clinical Trials: Application to Mesotheliomaâ€”The EORTC Lung Cancer Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 3007-3012.	0.8	38
117	Serial Measurements of Mesothelioma Serum Biomarkers in Asbestos-Exposed Individuals: A Prospective Longitudinal Cohort Study. <i>Journal of Thoracic Oncology</i> , 2011, 6, 889-895.	0.5	37
118	Randomized Trial of Surgery Versus Radiotherapy in Patients with Stage IIIA (N2) Nonâ€”Small-Cell Lung Cancer After a Response to Induction Chemotherapy: EORTC 08941. <i>Clinical Lung Cancer</i> , 2000, 2, 69-72.	1.1	34
119	Stage IIIA-N2 NSCLC: A review of its treatment approaches and future developments. <i>Lung Cancer</i> , 2009, 65, 257-267.	0.9	34
120	A randomized phase II study comparing induction or consolidation chemotherapy with cisplatinâ€”docetaxel, plus radical concurrent chemoradiotherapy with cisplatinâ€”docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2011, 22, 553-558.	0.6	34
121	Glomerular Filtration Rate Is a Confounder for the Measurement of Soluble Mesothelin in Serum. <i>Clinical Chemistry</i> , 2009, 55, 1431-1433.	1.5	33
122	Spherocytosis and pulmonary hypertension coincidental occurrence or causal relationship?. <i>European Respiratory Journal</i> , 1991, 4, 629-31.	3.1	32
123	Surgery in Mesothelioma â€” Where Do We Go after MARS?. <i>Journal of Thoracic Oncology</i> , 2013, 8, 525-529.	0.5	31
124	Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer â€” EORTC 08062. <i>European Journal of Cancer</i> , 2011, 47, 2322-2330.	1.3	30
125	Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. <i>European Journal of Cancer</i> , 2012, 48, 2983-2992.	1.3	30
126	Diagnostic and clinical features of lung cancer associated with cystic airspaces. <i>Journal of Thoracic Disease</i> , 2019, 11, 987-1004.	0.6	30

#	ARTICLE	IF	CITATIONS
127	Immunoreactivity for p-170 glycoprotein in malignant mesothelioma and in non-neoplastic mesothelium of the pleura using the murine monoclonal antibody JSB-1. <i>Journal of Pathology</i> , 1992, 167, 5-8.	2.1	29
128	The Yield of Endoscopic Ultrasound in Lung Cancer Staging: Does Lymph Node Size Matter?. <i>Journal of Thoracic Oncology</i> , 2008, 3, 245-249.	0.5	29
129	Radiation-induced oesophagitis in lung cancer patients. <i>Strahlentherapie Und Onkologie</i> , 2012, 188, 564-567.	1.0	29
130	BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1081-1088.	1.9	28
131	Development of a Multicomponent Prediction Model for Acute Esophagitis in Lung Cancer Patients Receiving Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 537-544.	0.4	27
132	What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 306-317.	2.0	27
133	Exhaled breath to screen for malignant pleural mesothelioma: a validation study. <i>European Respiratory Journal</i> , 2017, 50, 1700919.	3.1	27
134	Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review. <i>Translational Lung Cancer Research</i> , 2018, 7, 520-536.	1.3	27
135	Transesophageal Endoscopic Ultrasound with Fine Needle Aspiration in the Preoperative Staging of Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2008, 14, 6259-6263.	3.2	26
136	Mesothelioma treatment: Are we on target? A review. <i>Journal of Advanced Research</i> , 2015, 6, 319-330.	4.4	26
137	Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 113-124.	1.6	26
138	Lung cancer screening in Europe: where are we in 2021?. <i>Translational Lung Cancer Research</i> , 2021, 10, 2407-2417.	1.3	26
139	Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe. <i>Journal of Personalized Medicine</i> , 2022, 12, 72.	1.1	26
140	Proliferation in malignant mesothelioma as determined by mitosis counts and immunoreactivity for proliferating cell nuclear antigen (PCNA). <i>Journal of Pathology</i> , 1994, 172, 247-253.	2.1	25
141	Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 540-552.	5.1	25
142	FDG uptake by the bone marrow in NSCLC patients is related to TGF- β 2 but not to VEGF or G-CSF serum levels. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 519-522.	3.3	24
143	Small-cell lung cancer: local therapy for a systemic disease?. <i>Lancet</i> , The, 2015, 385, 9-10.	6.3	24
144	Screening for Mesothelioma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 781-782.	2.5	23

#	ARTICLE	IF	CITATIONS
145	Consensus report: Pretreatment minimal staging and treatment of potentially resectable malignant pleural mesothelioma. <i>Lung Cancer</i> , 2005, 49, S123-S127.	0.9	22
146	Effects of Whole Body Vibration in Patients With COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015, 12, 525-532.	0.7	22
147	A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205). <i>Translational Lung Cancer Research</i> , 2018, 7, 593-598.	1.3	22
148	Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma. <i>Oncotarget</i> , 2017, 8, 113673-113686.	0.8	21
149	Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis. <i>European Respiratory Review</i> , 2021, 30, 210057.	3.0	21
150	Spirometric Reference Values for an East-African Population. <i>Respiration</i> , 2013, 85, 297-304.	1.2	20
151	Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1994, 424, 631-634.	1.4	20
152	Safety and efficacy of AMG 655 in combination with paclitaxel and carboplatin (PC) in patients with advanced non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2009, 27, e19048-e19048.	0.8	20
153	Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody. <i>Lung Cancer</i> , 2017, 109, 74-77.	0.9	19
154	O 6 -Methylguanine-DNA methyltransferase (MGMT): A drugable target in lung cancer?. <i>Lung Cancer</i> , 2017, 107, 91-99.	0.9	19
155	A Literature Review of the Potential Diagnostic Biomarkers of Head and Neck Neoplasms. <i>Frontiers in Oncology</i> , 2020, 10, 1020.	1.3	19
156	Detection of malignant pleural mesothelioma in exhaled breath by multicapillary column/ion mobility spectrometry (MCC/IMS). <i>Journal of Breath Research</i> , 2016, 10, 046001.	1.5	18
157	The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3. <i>Cancers</i> , 2021, 13, 282.	1.7	18
158	GlutathioneS-transferase expression in malignant mesothelioma and non-neoplastic mesothelium: an immunohistochemical study. <i>Journal of Cancer Research and Clinical Oncology</i> , 1996, 122, 619-624.	1.2	17
159	Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a "chemosensitive" relapse: A single-arm phase II study (EORTC-08061). <i>European Journal of Cancer</i> , 2016, 54, 35-39.	1.3	17
160	LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. <i>Clinical Lung Cancer</i> , 2017, 18, 589-593.	1.1	17
161	A Multicenter Study to Assess EGFR Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical Setting. <i>Cancers</i> , 2018, 10, 290.	1.7	17
162	Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIET). <i>PLoS ONE</i> , 2016, 11, e0147599.	1.1	17

#	ARTICLE	IF	CITATIONS
163	Curative radiotherapy for a second primary lung cancer arising after pneumonectomy – techniques and results. <i>Radiotherapy and Oncology</i> , 2002, 62, 21-25.	0.3	16
164	Modern Radiotherapy as Part of Combined Modality Treatment in Locally Advanced Non-Small Cell Lung Cancer: Present Status and Future Prospects. <i>Oncologist</i> , 2008, 13, 700-708.	1.9	16
165	Raltitrexed in mesothelioma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1481-1490.	1.1	16
166	Prognostic Understanding and Quality of Life in Patients With Advanced Lung Cancer: A Multicenter Study. <i>Clinical Lung Cancer</i> , 2019, 20, e369-e375.	1.1	16
167	Strengths, Weaknesses, and Opportunities of Diagnostic Breathomics in Pleural Mesothelioma – A Hypothesis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 898-908.	1.1	15
168	The electronic nose: emerging biomarkers in lung cancer diagnostics. <i>Breathe</i> , 2019, 15, e135-e141.	0.6	15
169	Imaging of urgencies and emergencies in the lung cancer patient. <i>Insights Into Imaging</i> , 2018, 9, 463-476.	1.6	14
170	Coping Strategy Influences Quality of Life in Patients With Advanced Lung Cancer by Mediating Mood. <i>Clinical Lung Cancer</i> , 2021, 22, e146-e152.	1.1	14
171	Reply: Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 1138-1139.	0.5	13
172	Carbonic Anhydrase IX Expression Correlates with FDG Uptake by Primary Non-Small Cell Lung Cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 149-154.	0.7	13
173	Quality of care and variability in lung cancer management across Belgian hospitals: a population-based study using routinely available data. <i>International Journal for Quality in Health Care</i> , 2018, 30, 306-312.	0.9	13
174	Patterns of care for non-small cell lung cancer patients in Belgium: A population-based study. <i>European Journal of Cancer Care</i> , 2018, 27, e12747.	0.7	13
175	MA12.06 STELLAR – Final Results of a Phase 2 Trial of TTFIELDS with Chemotherapy for First-Line Treatment of Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, S397-S398.	0.5	13
176	Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations. <i>Translational Lung Cancer Research</i> , 2018, 7, 562-573.	1.3	13
177	Surgical treatment of iatrogenic tracheal lacerations. <i>Acta Chirurgica Belgica</i> , 1997, 97, 308-10.	0.2	13
178	Surgery or radiotherapy for early-stage lung cancer – a potential comparison bias. <i>Lancet Oncology</i> , 2013, 14, e390.	5.1	12
179	Routine implementation of EGFR mutation testing in clinical practice in Flanders: the HERMES™ project. <i>Acta Clinica Belgica</i> , 2014, 69, 92-97.	0.5	12
180	Real-life treatment practice for malignant pleural mesothelioma in Belgium. <i>Lung Cancer</i> , 2018, 125, 258-264.	0.9	12

#	ARTICLE	IF	CITATIONS
181	Willingness of pulmonologists to guide COPD patients in smoking cessation. <i>Patient Education and Counseling</i> , 2005, 57, 126-133.	1.0	11
182	What is the role for surgery in patients with stage III non-small cell lung cancer?. <i>Current Opinion in Pulmonary Medicine</i> , 2009, 15, 295-302.	1.2	11
183	Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation. <i>European Journal of Cancer</i> , 2014, 50, 2771-2782.	1.3	11
184	Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4182.	1.8	11
185	Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial. <i>Lung Cancer</i> , 2021, 153, 165-170.	0.9	11
186	Bevacizumab in pleural mesothelioma: too few, too late?. <i>Translational Cancer Research</i> , 2016, 5, 120-123.	0.4	11
187	Short-term survival after major pulmonary resections for bronchogenic carcinoma. <i>Acta Chirurgica Belgica</i> , 1996, 96, 273-9.	0.2	11
188	Quality assurance of thoracic radiotherapy in EORTC 08941: A randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy. <i>European Journal of Cancer</i> , 2006, 42, 1391-1398.	1.3	10
189	The controversial role of surgery in stage III NSCLC. <i>Lancet Oncology</i> , The, 2008, 9, 607-608.	5.1	10
190	Addressing the Palliative Setting in Advanced Lung Cancer Should Not Remain a Barrier: A Multicenter Study. <i>Clinical Lung Cancer</i> , 2017, 18, e283-e287.	1.1	10
191	Wolf in Sheep's Clothing: Primary Lung Cancer Mimicking Benign Entities. <i>Lung Cancer</i> , 2017, 112, 109-117.	0.9	10
192	Calculation of half-life of carcinoembryonic antigen after lung tumour resection: a case report. <i>European Respiratory Journal</i> , 1991, 4, 374-6.	3.1	10
193	Role of thoracoscopy (VATS) in pleural and pulmonary pathology. <i>Acta Chirurgica Belgica</i> , 1996, 96, 23-7.	0.2	10
194	Quantitative Perfusion Scintigraphy or Anatomic Segment Method in lung cancer resection. <i>Lung Cancer</i> , 2011, 74, 212-218.	0.9	9
195	The seventh tumour node metastasis staging system for lung cancer: Sequel or prequel?. <i>European Journal of Cancer</i> , Supplement, 2013, 11, 150-158.	2.2	9
196	Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1755-1765.	0.5	9
197	Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients. <i>Lung Cancer</i> , 2018, 124, 19-22.	0.9	9
198	An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA-loaded dendritic cells for cancer vaccination. <i>Cytotherapy</i> , 2018, 20, 1164-1181.	0.3	9

#	ARTICLE	IF	CITATIONS
199	Facts, rumours and speculations about the mesothelioma epidemic. <i>Respirology</i> , 2011, 16, 1018-1019.	1.3	8
200	Practical tools for implementing early palliative care in advanced lung cancer. <i>European Respiratory Journal</i> , 2016, 47, 1010-1012.	3.1	8
201	Local treatment of stage IIIA-N2 nonsmall cell lung cancer: surgery and/or radiotherapy. <i>Current Opinion in Oncology</i> , 2020, 32, 54-62.	1.1	8
202	DNA Methylation as a Diagnostic Biomarker for Malignant Mesothelioma: A Systematic Review and Meta-Analysis. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1461-1478.	0.5	8
203	Massive intestinal haemorrhage due to a solitary jejunal metastasis of a primary bronchogenic tumour. <i>Acta Chirurgica Belgica</i> , 1992, 92, 187-90.	0.2	8
204	Inaccurate clinical nodal staging of non-small cell lung cancer: evidence from the MRC LU22 multicentre randomised trial. <i>Thorax</i> , 2010, 65, 463-463.	2.7	7
205	Malignant pleural mesothelioma: when is radiation therapy indicated?. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 551-560.	1.1	7
206	Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study). <i>European Journal of Cancer Care</i> , 2014, 23, 370-379.	0.7	7
207	Extrapleural pneumonectomy: still indicated?. <i>Translational Lung Cancer Research</i> , 2018, 7, 550-555.	1.3	7
208	Association between surgical volume and post-operative mortality and survival after surgical resection in lung cancer in Belgium: A population-based study. <i>European Journal of Surgical Oncology</i> , 2019, 45, 2443-2450.	0.5	7
209	A rare case of inflammatory pseudotumour of the bronchus, occurring in an achondroplastic woman. <i>European Respiratory Journal</i> , 1994, 7, 826-828.	3.1	6
210	C5-03: Open-label study of pemetrexed alone or in combination with a platinum for previously treated patients (pts) with malignant pleural mesothelioma (MPM): Outcomes from the International Expanded Access Program (EAP). <i>Journal of Thoracic Oncology</i> , 2007, 2, S372-S373.	0.5	6
211	Neoadjuvant chemotherapy in the treatment of nonsmall-cell lung cancer. <i>Current Opinion in Oncology</i> , 2007, 19, 92-97.	1.1	6
212	Investigational Approaches for Mesothelioma. <i>Frontiers in Oncology</i> , 2011, 1, 22.	1.3	6
213	Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERA-VOLT Experience. <i>Cancer Cell</i> , 2020, 38, 602-604.	7.7	6
214	Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma. <i>Journal of Thoracic Oncology</i> , 2006, 1, S32-6.	0.5	6
215	O-273 Induction chemotherapy (CT) in stage IIIA-N2 non-small cell lung cancer (NSCLC): An analysis of different regimens used in EORTC 08941. <i>Lung Cancer</i> , 2003, 41, S79-S80.	0.9	5
216	Adjuvant or neoadjuvant chemotherapy in minimal N2 stage IIIA nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2010, 22, 102-111.	1.1	5

#	ARTICLE	IF	CITATIONS
217	Endobronchial metallic clips to guide high-dose external-beam radiotherapy in radio-occult lung cancer. <i>European Respiratory Journal</i> , 2010, 36, 965-967.	3.1	5
218	European guidelines for the management of malignant pleural mesothelioma. <i>Journal of Advanced Research</i> , 2011, 2, 281-288.	4.4	5
219	P2.01-093 Exo-ALK Proof of Concept: Exosomal Analysis of ALK Alterations in Advanced NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, S844-S845.	0.5	5
220	The use of patient-reported outcome measures (PROMs) in the management of malignant pleural mesothelioma: a descriptive literature survey. <i>Translational Lung Cancer Research</i> , 2018, 7, 507-515.	1.3	5
221	Evaluation of mediastinoscopy in mediastinal lymph node staging for non-small-cell lung cancer. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2021, 32, 270-275.	0.5	5
222	What is the optimal treatment of stage IIIA–N2 non-small-cell lung cancer after EORTC 08941?. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 199-206.	1.1	4
223	Mesothelin Levels in Urine are Affected by Glomerular Leakage and Tubular Reabsorption. <i>Clinical Lung Cancer</i> , 2012, 13, 470-474.	1.1	4
224	Estimation of post-operative forced expiratory volume by functional respiratory imaging. <i>European Respiratory Journal</i> , 2015, 45, 544-546.	3.1	4
225	193TiP: CheckMate 171: A multicenter phase 2 trial of nivolumab (nivo) in patients (pts) with stage IIIB/IV squamous cell (SQ) NSCLC who have received ≥1 prior systemic treatment. <i>Journal of Thoracic Oncology</i> , 2016, 11, S141.	0.5	4
226	Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in cancer patients. <i>Annals of Oncology</i> , 2016, 27, vi15.	0.6	4
227	Lung Cancer in Belgium. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1610-1621.	0.5	4
228	Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma. <i>Biomedicines</i> , 2022, 10, 673.	1.4	4
229	Salmonella Typhimurium Empyema in An AIDS Patient. <i>International Journal of STD and AIDS</i> , 1995, 6, 287-288.	0.5	3
230	B5-06: Mature results of PulmonArt: Involved-field 3D radiotherapy (RT) and docetaxel/cisplatin chemotherapy (CT) in a randomised phase 2 study comparing concurrent CT-RT followed by consolidation CT, with induction CT followed by concurrent CT-RT in patients (pts) with stage III non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2007, 2, S349-S350.	0.5	3
231	Monitoring EGFR TKI resistance in real time using ddPCR-based liquid biopsy: a case report. <i>Journal of Clinical Pathology</i> , 2018, 71, 754-756.	1.0	3
232	Assessing the completeness and correctness of the registration of malignant mesothelioma in Belgium. <i>Lung Cancer</i> , 2018, 122, 38-43.	0.9	3
233	Molecular analysis of an asbestos-exposed Belgian family with a high prevalence of mesothelioma. <i>Familial Cancer</i> , 2018, 17, 569-576.	0.9	3
234	Molecular profiling in lung cancer associated with cystic airspaces. <i>Acta Clinica Belgica</i> , 2021, 76, 158-161.	0.5	3

#	ARTICLE	IF	CITATIONS
235	European guidelines for the management of malignant pleural mesothelioma. Polish Archives of Internal Medicine, 2010, 120, 503-510.	0.3	3
236	Malignant pleural and peritoneal mesothelioma: clinical update 2018. Translational Lung Cancer Research, 2018, 7, 505-506.	1.3	3
237	Intrapulmonary lymph nodes in the differential diagnosis of solitary pulmonary nodules: case report and review of the literature. Acta Chirurgica Belgica, 1995, 95, 130-2.	0.2	3
238	Headspace Volatile Organic Compound Profiling of Pleural Mesothelioma and Lung Cancer Cell Lines as Translational Bridge for Breath Research. Frontiers in Oncology, 2022, 12, .	1.3	3
239	P-410 Prognostic factor analysis of EORTC 08983: A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM). Lung Cancer, 2005, 49, S223.	0.9	2
240	Response: Re: Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2007, 99, 1210-1211.	3.0	2
241	Palliative chemotherapy: Do we need yet another end-point?. European Journal of Cancer, 2009, 45, 2234-2235.	1.3	2
242	Novel treatment options in stage I non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2014, 14, 1007-1020.	1.1	2
243	Illness understanding in patients with advanced lung cancer: curse or blessing?. Annals of Palliative Medicine, 2016, 5, 135-138.	0.5	2
244	Malignant pleural mesothelioma: single-institution experience of 101 patients over a 15-year period. Acta Chirurgica Belgica, 2017, 117, 157-163.	0.2	2
245	International trends in the clinical epidemiology of malignant pleural mesothelioma. Journal of Thoracic Disease, 2018, 10, 1147-1148.	0.6	2
246	PL02.09 Nintedanib + Pemetrexed/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME-Meso Trial. Journal of Thoracic Oncology, 2018, 13, S186.	0.5	2
247	Lung cancer staging: imagine fewer images. European Respiratory Journal, 2018, 52, 1801093.	3.1	2
248	Why Did the Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC Not Reveal a Difference?. Journal of Thoracic Oncology, 2021, 16, e42-e45.	0.5	2
249	Short Report from the European Society of Medical Oncology: Oral Abstracts on Mesothelioma. Journal of Thoracic Oncology, 2007, 2, 101.	0.5	2
250	Targeted adjuvant therapy in non-small cell lung cancer: trick or treat?. European Respiratory Journal, 2021, 58, 2101637.	3.1	2
251	Cons: long-term CT-scan follow-up is not the standard of care in patients curatively treated for an early stage non-small cell lung cancer. Translational Lung Cancer Research, 2015, 4, 479-83.	1.3	2
252	Chemotherapy in malignant mesothelioma: what's up, doc?. Journal of Thoracic Oncology, 2006, 1, 279-80.	0.5	2

#	ARTICLE	IF	CITATIONS
253	European guidelines for the management of malignant pleural mesothelioma. , 2010, 120, 503-10.		2
254	End of life care in lung cancer patients: not at life's end?. Annals of Palliative Medicine, 2013, 2, 167-9.	0.5	2
255	Pemetrexed in thoracic cancer. Expert Opinion on Pharmacotherapy, 2006, 7, 917-928.	0.9	1
256	The Sound of the Parasite. Diagnosing Mediastinal Cysts with Endoscopic Ultrasound Techniques. Respiration, 2008, 75, 98-99.	1.2	1
257	A Guide to Staging in Lung Cancer, but Potentially Misleading without Attention to the Details. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 209-210.	2.5	1
258	The Role of EBUS-TBNA for the Assessment of Hilar Lymph Nodes. Journal of Thoracic Oncology, 2010, 5, 410.	0.5	1
259	Pleural Nodules and Mediastinal Lymphadenopathy in a Smoker: An Unusual Case Report. Case Reports in Oncology, 2016, 9, 488-492.	0.3	1
260	P2.06-027 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S1087-S1088.	0.5	1
261	Reply to K. Masuda et al. Journal of Clinical Oncology, 2019, 37, 2294-2295.	0.8	1
262	Osimertinib in patients with advanced/metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer - the Belgian ASTRIS data. Acta Clinica Belgica, 2021, 76, 224-231.	0.5	1
263	Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy. PLoS ONE, 2021, 16, e0252646.	1.1	1
264	Reaction on the Interpretation of the Hippocampus Avoidance Prophylactic Cranial Irradiation Trial in SCLC (NCT01780675). Journal of Thoracic Oncology, 2021, 16, e63-e65.	0.5	1
265	Disseminated lung cancer or extragonadal germ cell tumour?. European Respiratory Journal, 1991, 4, 84-7.	3.1	1
266	Lung cancer in Europe: The way forward. Tobacco Prevention and Cessation, 2022, 8, 1-2.	0.2	1
267	External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma. Cancers, 2022, 14, 3182.	1.7	1
268	New Implications of Patients's Sex in Today's Lung Cancer Management. Cancers, 2022, 14, 3399.	1.7	1
269	Neoadjuvant chemotherapy in early stage non-small cell lung cancer. European Journal of Cancer, Supplement, 2007, 5, 377-379.	2.2	0
270	PD1-2-5: Mediastinal Lymph Node Staging in lung cancer by integrated FDG-PET/CT based SUV value calculation. A prospective series. Journal of Thoracic Oncology, 2007, 2, S418-S419.	0.5	0

#	ARTICLE	IF	CITATIONS
271	The emerging role for combined endosonography with fine needle aspiration in lung cancer staging: is the scope the right one?†. <i>European Journal of Cardio-thoracic Surgery</i> , 2010, 38, 647-647.	0.6	0
272	Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 99-104.	2.2	0
273	Novel treatment options in early-stage non-small-cell lung cancer. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 264-265.	2.2	0
274	A rare cause of haemoptysis. <i>Acta Clinica Belgica</i> , 2014, 69, 69-73.	0.5	0
275	SP-0103: Better systemic therapy. <i>Radiotherapy and Oncology</i> , 2016, 119, S47-S48.	0.3	0
276	Money rules the world. <i>Lung Cancer</i> , 2016, 91, 77-78.	0.9	0
277	SC06.04 Immunotherapy of Malignant Pleural Mesothelioma and Thymic Malignancies: The End of the Beginning?. <i>Journal of Thoracic Oncology</i> , 2017, 12, S92-S94.	0.5	0
278	P3.05-019 Patients with Advanced Lung Cancer: What Do They Know, What Would They Like to Know, What Should They Know about Their Disease. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1423-S1424.	0.5	0
279	OA02.07 Characterization of the Tumor Microenvironment and Investigation of Immune Checkpoint Expression in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017, 12, S249-S250.	0.5	0
280	OA22.05 Breath Analysis by Gas Chromatography-Mass Spectrometry Can Be Used to Screen for Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017, 12, S331.	0.5	0
281	P2.06-36 EORTC 1205: Randomized Phase II Study of Pleurectomy/Decortication Preceded or Followed by Chemotherapy in Early Stage MPM. <i>Journal of Thoracic Oncology</i> , 2018, 13, S756-S757.	0.5	0
282	Aminopeptidase antibodies in mesothelioma: new wine deserves new sacks. <i>European Respiratory Journal</i> , 2018, 51, 1800817.	3.1	0
283	Continuous professional development: elevating thoracic oncology education in Europe. <i>Breathe</i> , 2019, 15, 279-285.	0.6	0
284	P2.04-44 Combined Immune Checkpoint Blockade in Mesothelioma: In Vivo Investigation of in Vitro Data. <i>Journal of Thoracic Oncology</i> , 2019, 14, S725.	0.5	0
285	P1.06-06 EORTC 1205: Randomized Study of Pleurectomy/Decortication (P/D) Preceded or Followed by Chemotherapy in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2019, 14, S479.	0.5	0
286	Oxygen saturation measured in vivo in bronchial tumors during bronchoscopy in patients with lung cancer using differential path length spectroscopy (DPS) correlates with survival, stage of the disease, and expression of HIF1a. <i>Journal of Clinical Oncology</i> , 2006, 24, 10084-10084.	0.8	0
287	New American College of Chest Physicians guidelines on mediastinal staging and management of stage IIIA-N2 non-small cell lung cancer: a European perspective. <i>Polish Archives of Internal Medicine</i> , 2008, 118, 175-178.	0.3	0
288	Treatment recommendations by clinicians in stage I non-small cell lung cancer: better work-up leads to less discussion. <i>Annals of Translational Medicine</i> , 2017, 5, 427-427.	0.7	0

#	ARTICLE	IF	CITATIONS
289	Radiotherapy for single station N2 NSCLC. Translational Lung Cancer Research, 2014, 3, 234-7.	1.3	0
290	Rebuttal from Dr van Meerbeeck. Translational Lung Cancer Research, 2015, 4, 485-6.	1.3	0
291	Malignant fibrous histiocytoma of the pulmonary artery. European Journal of Respiratory Diseases, 1987, 71, 321-3.	0.4	0
292	Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)? Oncotarget, 2022, 13, 800-809.	0.8	0